CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

etavopivat

Small moleculeexperimental

Clinical trial activity

14 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
7
Phase 3
3
Phase 4
0

Earliest trial started Dec 11, 2018 (NCT03815695)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C([C@H](CO)c1ccccc1)N1CC2=C(C1)CN(S(=O)(=O)c1cnc3c(c1)OCCO3)C2
Mol. weight
457.51 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07023029Phase 1Jun 9, 2025Novo Nordisk
NCT06813924Phase 1Feb 6, 2025Novo Nordisk
NCT06612268Phase 3Dec 16, 2024Novo Nordisk
NCT06609226Phase 3Dec 9, 2024Novo Nordisk
NCT06581627Phase 1Aug 26, 2024Novo Nordisk
NCT06336018Phase 1Jun 4, 2024Novo Nordisk
NCT06433661Phase 1May 28, 2024Novo Nordisk
NCT05725902Phase 2Nov 29, 2023Emory University, Forma Therapeutics, Inc.
NCT05953584Phase 2Jun 20, 2023Forma Therapeutics, Inc., Novo Nordisk
NCT06198712Phase 1/Phase 2 (Phase 2)Feb 7, 2023Forma Therapeutics, Inc., Novo Nordisk
NCT05568225Phase 2Nov 22, 2022Forma Therapeutics, Inc.
NCT04987489Phase 2Sep 30, 2021Forma Therapeutics, Inc.
NCT04624659Phase 2/Phase 3 (Phase 3)Dec 31, 2020Forma Therapeutics, Inc.
NCT03815695Phase 1Dec 11, 2018Forma Therapeutics, Inc., Medpace, Inc.
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Novo NordiskFor profit9732023
Forma Therapeutics, Inc.For profit7732018
Emory UniversityAcademic/Hospital1012023
Medpace, Inc.For profit1012018
4 organizations
Page 1 / 1